2 news items
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
COCP
13 May 24
program, preparations are underway to initiate a Phase 1 study in healthy volunteers with inhaled CC-42344 as a potential prophylactic
Cocrystal Pharma Receives Pre-IND Responses From The FDA On Oral CC-42344 For Treating Influenza A
COCP
19 Mar 24
and clinical measures in healthy volunteers who are infected with the influenza A virus. The Company expects to report topline results from this study
- Prev
- 1
- Next